T h e ne w e ngl a nd jou r na l o f m e dicine I nfants who are small for gestational age or have impaired postnatal linear growth continue to be of major concern with regard to public health in low-and middle-income countries. 1, 2 However, environmental and dietary regulation of fetal and infant growth remain inadequately understood. Observational studies have shown numerous early-life risk factors for later anthropometric outcomes, 3, 4 but there is limited evidence of benefit of prenatal micronutrient interventions on childhood linear growth. 5 Vitamin D may influence fetal and postnatal growth through effects on calcium absorption, 6 parathyroid hormone expression, 7 phosphate metabolism, 8 growth-plate function, 9 ,10 and regulation of the insulin-like growth factor axis.
11 Metaanalyses of observational studies 12 and clinical trials 13 have suggested that vitamin D may have a beneficial effect on fetal growth, but most previous trials have had methodologic limitations. 13 In a previous small trial in Bangladesh, we found that early postnatal linear growth was higher in infants born to women who had received vitamin D supplementation as compared with those who had not received supplementation. 14 In Bangladesh, approximately 30% of newborns are small for gestational age, 1 and the growth of 36% of children younger than 5 years of age is stunted (height-for-age z score, <−2). 15 Vitamin D deficiency is common in Bangladeshi women of reproductive age. 16 In the Maternal Vitamin D for Infant Growth (MDIG) trial conducted in Dhaka, Bangladesh, we evaluated the dose-dependent effects of prenatal vitamin D supplementation, with and without postpartum supplementation, on infant growth and other maternal, newborn, and infant outcomes.
Me thods

Trial Design and Oversight
The MDIG trial was a randomized, double-blind, placebo-controlled, dose-ranging trial of maternal vitamin D supplementation. 17 The protocol is available with the full text of this article at NEJM.org, and the statistical analysis plan is included in the Supplementary Appendix, also available at NEJM .org. The trial was overseen by a steering committee and an independent data and safety monitoring board. The protocol was approved by research ethics committees at the Hospital for Sick Children in Toronto and the International Center for Diarrheal Disease Research, Bangladesh (icddr,b). All authors attest to the completeness and accuracy of the data and analyses and for the adherence of the trial to the protocol. The trial funder had no role in the trial design, data collection and analysis, or interpretation of the results. No support from a commercial entity was provided.
Participants
Participants were generally healthy pregnant women between 17 and 24 weeks of gestation. They were enrolled after providing written informed consent between March 2014 and September 2015 at the Maternal and Child Health Training Institute, a public hospital in Dhaka, Bangladesh. The criteria for inclusion and exclusion are shown in Table S1 in the Supplementary Appendix.
Interventions
Participants were randomly assigned at enrollment to one of five groups to receive vitamin D or placebo. One group received placebo throughout the prenatal period and for 26 weeks post partum. Three groups received prenatal supplementation only, in the following doses: 4200 IU per week (prenatal 4200 group), 16,800 IU per week (prenatal 16,800 group), or 28,000 IU per week (prenatal 28,000 group). The fifth group received prenatal supplementation as well as 26 weeks of postpartum supplementation in the amount of 28,000 IU per week (prenatal and postpartum 28,000 group). A computer-generated, simple randomization scheme was created independently by the trial statistician. The master list linking participant identifiers to supplementation groups was held by the supplement manufacturer and not accessed by any trial personnel until final group assignments were revealed. Concealment of trial-group assignments was ensured with the use of prelabeled and sequentially numbered but otherwise identical supplement vials, which were provided to participants in accordance with the assignment sequence. Oral vitamin D 3 and placebo tablets were manufactured by the Toronto Institute for Pharmaceutical Technology (Toronto). The vitamin D content of each batch of tablets was verified in product testing. 17 Tablets with different doses were identical in appearance and taste. Tablets were routinely administered under direct observation by trial personnel; however, up to four consecutive doses may have been unobserved Vitamin D in Pregnancy and Lactation and Infant Growth when participants were unavailable for scheduled visits. Missed doses were administered up to 7 days after the scheduled date. Calcium (500 mg per day), iron (66 mg per day), and folic acid (350 μg per day) were provided to all participants throughout the intervention phase. 17 If a participant reported use of a vitamin D or a calcium supplement for more than 1 week that had not been provided through the trial, trial supplements were suspended until nontrial supplement use was discontinued. Supplementation was discontinued in participants with confirmed hypercalcemia (as defined below), fetal or infant death, or a new condition or medication that could alter vitamin D metabolism.
Assessments and Outcomes
Trial personnel contacted participants weekly from enrollment until 26 weeks post partum, and infants were further assessed at 9 months and 12 months of age. Visits were conducted in the home or at a clinic and included the use of standardized questionnaires, point-of-care tests, anthropometric measurements, and specimen collection (Table S2 in the Supplementary Appendix). Data on socioeconomic and household characteristics were collected at baseline. Weekly prenatal questionnaires included health care encounters and a checklist of clinical symptoms. Postnatal followup visits included assessment of both the infant's health and feeding practices as well as a basic physical examination. Maternal blood pressure was measured at enrollment, at 24 and 30 weeks of gestation, and weekly from 36 weeks of gestation to delivery. Trial personnel tracked pregnancy outcomes, visits with trial physicians, hospitalizations, and deaths, and they attended all facilitybased deliveries and home births when feasible. Participants were provided with free medical care and encouraged to seek medical attention from trial physicians and to notify trial personnel of concerns about their health. Infant crown-to-heel length (to the last completed millimeter), head circumference, upper-arm length, mid-upper-arm circumference, and rumpto-knee length -all to the last completed millimeter -and weight (to the nearest 5 g up to 10 kg and to the nearest 10 g for >10 kg) were measured by trained personnel according to standardized procedures 17 adapted from the protocols of the INTERGROWTH-21st (International Fetal and Newborn Growth Consortium for the 21st Century) Project. 18 Each measurement was obtained independently by two trial personnel and repeated if the difference between paired measurements exceeded specified thresholds. Means of the final pair of values were used in analyses. Interrater reliability was high, and few measurements were excluded due to implausibility or temporal inconsistencies (see Methods, section 1, and Table S3 in the Supplementary Appendix). 19 Length, weight, weight for length, body-mass index, head circumference, and mid-upper-arm circumference were expressed as sex-and age-(or gestational age-) standardized z scores according to INTERGROWTH-21st standards for newborn size, 20 postnatal growth standards for preterm infants to 64 weeks of postmenstrual age (weight, length, and head circumference only), 21 or World Health Organization (WHO) child growth standards.
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The primary outcome was length-for-age z score at 1 year (364 to 420 days). Secondary outcomes included other infant anthropometric variables; preterm birth (<37 weeks of gestation); gestational hypertension; delivery characteristics; stillbirth; mother and infant symptoms, clinical encounters, and hospitalizations; deaths; congenital anomalies; infant neurologic disabilities; and infant rickets (for a complete list of secondary outcomes, see Table S4 in the Supplementary Appendix). Biochemical screening for rickets was scheduled at 6 months of age (see Methods, section 2, in the Supplementary Appendix). Radiologic confirmation was based on interpretations of images of the wrist, knee, or both by a pediatric radiologist who was unaware of other data. Post hoc classifications of infants' neurologic disabilities, congenital anomalies, and physician-assigned diagnostic codes for clinical encounters and hospitalizations were made by trial investigators who were unaware of treatment allocation.
The primary safety measure was maternal total serum calcium concentration at enrollment, 30 weeks of gestation, delivery, 3 months and 6 months post partum, or during hospitalization (if feasible). "Possible hypercalcemia" was defined as any serum calcium concentration of more than 2.60 mmol per liter (>10.4 mg per deciliter), and "confirmed hypercalcemia" (primary safety outcome) as a serum calcium concentration greater than 2.60 mmol per liter on a repeat specimen T h e ne w e ngl a nd jou r na l o f m e dicine or a single serum calcium concentration greater than 2.80 mmol per liter (>11.2 mg per deciliter).
Secondary safety indicators included the serum calcium concentration of infants at 3 and 6 months of age and the urinary calcium:creatinine ratio of mothers at delivery. "Possible hypercalciuria" in mothers was defined as a single urinary calcium:creatinine ratio of more than 1, with both calcium and creatinine measured in millimoles (or >0.35, with both measured in milligrams). Participants with a urinary calcium:creatinine ratio of more than 1 in two consecutive specimens (i.e., confirmed hypercalciuria), symptoms of renal colic, or both underwent ultrasonography for urolithiasis or nephrolithiasis. Infant urinary calcium:creatinine ratios were measured at 6 months of age. Serum calcium concentrations and urinary calcium:creatinine ratios were analyzed at icddr,b.
Vitamin D status was based on serum 25-hydroxyvitamin D 23 concentration, with deficiency defined as a concentration below 30 nmol per liter (<12 ng per milliliter). 24 The C3-epimer fraction was included only in sensitivity analyses. Measurement of 25-hydroxyvitamin D and intact parathyroid hormone (iPTH) was conducted by the Analytical Facility for Bioactive Molecules at the Hospital for Sick Children, Toronto (Methods, section 3, in the Supplementary Appendix).
Statistical Analysis
The primary analysis was a complete-case intention-to-treat analysis. Analysis of variance was performed to compare length-for-age z scores at 1 year of age across all groups. To estimate the effect of weekly administration of prenatal vitamin D, five pairwise comparisons were conducted with the use of t-tests: prenatal 4200 versus placebo, prenatal 16,800 versus placebo, prenatal 16,800 versus prenatal 4200, prenatal 28,000 versus placebo, and prenatal 28,000 versus prenatal 16,800. Statistical significance was tested with a two-sided alpha level of 0.05, with the Holm test applied for multiple comparisons. 25 The determination of sample size was based on the conservative assumption that if each between-group comparison had a two-sided alpha of 0.01 and 90% power, 220 participants per group would enable detection of a between-group difference in length-for-age z score of at least 0.40.
14 To accommodate an attrition rate of 15%, we aimed to enroll 260 pregnant women in each group.
The effect of postpartum vitamin D on lengthfor-age z score at 1 year of age was assessed by means of a pairwise comparison of the prenatal and postpartum 28,000 group with the prenatal 28,000 group (with a two-sided alpha level of 0.05) with the use of a t-test. Secondary outcomes were compared across groups with the use of analysis of variance for continuous, normally distributed variables and with the Kruskal-Wallis tests for skewed distributions; chi-square and Fischer's exact tests were used for categorical variables. Zeroinflated negative binomial models were used to compare incidence rates of clinical encounters, hospitalizations, and other adverse events. When the result of a global test was significant (P<0.05), post hoc pairwise comparisons were performed, with the Holm test applied for multiple comparisons. 25 We did not control for the multiplicity of comparisons of the secondary outcomes; any significant differences were viewed as exploratory. We conducted sensitivity and stratified analyses of the primary outcome and multiple imputation with chained equations to account for missing anthropometric data at 1 year of age. Trajectories of infant length-for-age z scores and other anthropometric measures were estimated with the use of restricted cubic spline regression models. Per-protocol analyses were restricted to participants who consumed at least 90% of scheduled supplement doses and had no episodes of reported consumption of nontrial vitamin D or calcium (see Methods, sections 4 to 7, in the Supplementary Appendix for additional details). Analyses were performed with the use of Stata, version 13 (StataCorp).
R esult s
Trial Population
A total of 1300 pregnant women were enrolled and randomly assigned to one of five groups (Fig.  S1 in the Supplementary Appendix). Baseline characteristics, including vitamin D status, were similar across groups (Table 1, and Tables S5 and  S6 in the Supplementary Appendix). Overall, 64% of women had vitamin D deficiency. The groups did not differ significantly with regard to breastfeeding patterns or reported use of micronutrient supplements by infants (Tables S7 and S8 in the Supplementary Appendix). Participants in primary analyses had higher average household-asset indexes than those who were excluded from pri-Vitamin D in Pregnancy and Lactation and Infant Growth mary analyses, but their characteristics were otherwise similar (Table S9 in the Supplementary  Appendix) . Across all groups, at least 90% of scheduled doses were received by more than 90% of women during the prenatal period and by more than 80% of women during the postpartum period (Table S10 in the Supplementary Appendix).
Infant Growth
Infant follow-up at 1 year of age was completed for 90% of pregnancies and 94% of infants who were alive at 1 year (Fig. S1 in the Supplementary Appendix). Overall, the mean (±SD) lengthfor-age z score at 1 year was −1.00±1.04, and the prevalence of stunting (length-for-age z score, <−2) was 16%. Prenatal or postpartum maternal vitamin D supplementation had no significant effect on infant length or other anthropometric outcomes by 1 year of age ( Table 2 , and Figs. S2 through S6 and Tables S11 and S12 in the Supplementary Appendix). The lack of effect of prenatal vitamin D on length was evident from birth (Table 3) and was supported by sensitivity and stratified analyses (Tables S13 through S22 in the Supplementary Appendix). Results of multiple imputation analyses (prespecified for lengthfor-age z score and post hoc for other 1-year anthropometric measurements) were consistent with the complete-case analyses (Table S18 in the Supplementary Appendix); therefore, completecase analyses only are shown in Table 2 .
Biochemical Effects of Supplementation
Vitamin D had dose-dependent effects on concentrations of maternal, cord blood, and infant 25-hydroxyvitamin D (Table 3 and Fig. 1, and  Tables S23 and S24 in the Supplementary Appendix) and on concentrations of maternal iPTH at delivery. The prenatal and postpartum 28,000 group continued to have significantly lower iPTH concentrations at 6 months post partum than the other groups (Fig. 1, and Table S25 in the Supplementary Appendix).
Safety and Clinical Outcomes
There were no episodes of confirmed hypercalcemia during pregnancy. Confirmed hypercalcemia (asymptomatic) occurred post partum in eight women (0.7%) -with five in the prenatal and postpartum 28,000 group -and in six infants (0.6%) -with two in the prenatal and postpartum 28,000 group; frequencies did not significantly differ across groups (Table S25 in the Supplementary Appendix) . Although prenatal vitamin D supplementation led to modest elevations in maternal, fetal, and infant mean serum calcium concentrations, at 6 months post partum only the mothers in the prenatal and postpartum 28,000 group continued to have higher calcium concentrations than those in the placebo group (in post hoc comparisons) (see Table S26 in the Supplementary Appendix). The maternal urinary calcium:creatinine ratio at delivery varied significantly across groups, with the median urinary calcium:creatinine ratio for the placebo group being the lowest. The risk of possible maternal hypercalciuria at delivery increased with dose; however, only the prenatal and postpartum 28,000 group differed significantly from the placebo group (as determined in a pairwise comparison after correcting for multiple testing with the use of the Holm test). There were two asymptomatic cases of maternal confirmed hypercalciuria, one each in the placebo group and the prenatal and postpartum 28,000 group. None of the women with confirmed hypercalcemia or confirmed hypercalciuria had serious adverse events (hospitalizations or deaths) or urinary tract stones. Two of the six infants with confirmed hypercalcemia had neonatal hospitalizations for acute illnesses that antedated and were clinically unrelated to hypercalcemia. There was one infant -in the prenatal 4200 group -with confirmed hypercalciuria. There were no significant differences across groups in infant urinary calcium:creatinine ratios at 6 months of age. Detailed biochemical safety data are shown in Tables S25, S26 , and S27 in the Supplementary Appendix.
Groups did not significantly differ in the frequencies of hospitalizations or deaths (Table S27 in the Supplementary Appendix). There were no significant beneficial or harmful effects of any vitamin D dose on gestational hypertension, duration of gestation, preterm birth, small size for gestational age (weight for gestational age, <10th percentile 20 ), low birth weight (<2500 g), other delivery outcomes, maternal or infant morbidity, maternal self-reported or caregiver-reported infant symptoms, or stillbirth (Table 3, and  Tables S27 through S33 in the Supplementary Appendix). Among four infants with radiologically confirmed rickets, three were in the placebo group T h e ne w e ngl a nd jou r na l o f m e dicine Post hoc pairwise comparisons conducted with the use of t-tests showed significant pairwise differences in maternal height between the prenatal and postpartum 28,000 group and the prenatal 28,000 group, after adjustment for multiple comparisons conducted with the Holm test. ¶ Calculations were based on 253 participants in the placebo group, 258 participants each in the prenatal 4200 group, the prenatal 16,800 group, and the prenatal 28,000 group, and 256 participants in the prenatal and postpartum 28,000 group. Vitamin D deficiency was defined as a concentration of 25-hydroxyvitamin D of <30 nmol per liter (<12 ng per milliliter).
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and one was in the prenatal 4200 group (Table S27 in Supplementary Appendix).
Discussion
In a region of the world where there is widespread vitamin D deficiency and fetal-infant growth restriction, vitamin D supplementation from midpregnancy to delivery or 6 months post partum had no significant effect on length-for-age z scores at 1 year or on other anthropometric measures from birth to 1 year. Similarly, vitamin D supplementation had no significant effect on numerous clinical outcomes during pregnancy or infancy. These findings do not support the hypothesis that prenatal vitamin D status in the second half of pregnancy is a determinant of newborn size. Our findings are contrary to the conclusions of earlier meta-analyses of observational studies 12 and mostly small trials 13 but consistent with those of higher-quality trials in areas where the prevalence of vitamin D deficiency and fetal growth restriction is lower. [26] [27] [28] [29] Our earlier trial, also conducted in Bangladesh, 14 and a trial in the United Kingdom 30 showed that prenatal vitamin D supplementation increased infant linear growth. However, these studies were small, each involving fewer than 135 participants, and included postnatal growth as a post hoc outcome, and the between-group differences may have been due to chance. A meta-analysis of six trials of prenatal, multiple-micronutrient supplementation that included relatively low doses of vitamin D (200 to 400 IU per day) in low-and middle-income countries showed no effect on height at 2 to 8.5 years of age. 5 The findings of our current trial confirm the lack of effect on growth across a range of prenatal doses of vitamin D up to 28,000 IU per week (the equivalent of approximately 4000 IU per day).
Effects on fetal or infant growth were absent despite the robust dose-response effects of vitamin D on serum concentrations of 25-hydroxyvitamin D, iPTH, and calcium and on the urinary calcium:creatinine ratio. The dose that was equivalent to the dietary allowance recommended by the Institute of Medicine 24 (4200 IU per week) was sufficient for eliminating maternal vitamin D deficiency (defined as a 25-hydroxyvitamin D concentration <30 nmol per liter) in nearly all women without elevating 25-hydroxyvitamin D concentration above a conservative long-term risk thresh-
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In nearly all women who received supplementation of 16,800 IU per week, concentrations of 25-hydroxyvitamin D did not fall below 50 nmol per liter (<20 ng per milliliter). In these women there was also maximal suppression of iPTH concentrations, and cord concentrations of 25-hydroxyvitamin D did not fall below 30 nmol per liter. Maternal postpartum supplementation of 28,000 IU per week maintained infant 25-hydroxyvitamin D concentrations at or above 30 nmol per liter up to 6 months of age, despite variation in feeding patterns. Although higher vitamin D doses increased serum calcium and urinary calcium excretion, hypercalcemia and hypercalciuria were infrequent, even in the group receiving the highest dose, and clinical adverse events did not differ significantly across groups.
There were no apparent benefits of improved vitamin D status in the latter half of pregnancy on pregnancy, birth, or infant outcomes, even without adjustment for multiplicity of testing for numerous secondary efficacy outcomes. Consistent with the findings of a recent meta-analysis, 13 we did not find a reduction in the incidence of preterm births. The occurrence of four cases of rickets in the placebo group and the prenatal 4200 group raised the possibility that doses of 16,800 IU per week or higher prenatally may prevent the development of early rickets, but there were too few cases to assess this question. Our trial was not powered to detect differences in infrequent maternal and infant adverse outcomes. Furthermore, the initiation of vitamin D supplementation in midpregnancy did not address the question of whether earlier supplementation might have had beneficial effects. Other potential limitations of the trial were that effects of vitamin D may have been attenuated by cosupplementation with calcium and that untreated maternal nutritional deficits may have limited the effects of vitamin D on fetal growth. Faltering of linear growth was milder in our trial participants than in a recent Bangladeshi national survey, 15 which suggests that participants had relatively better baseline health and access to care; for example, participants had high rates of facility deliveries (85% vs. 37% nationally).
15
At this time, the WHO does not recommend routine vitamin D supplementation during pregnancy. 31 The present findings support this position, even in communities where vitamin D de- † P values for multiple group comparisons are from analysis of variance or Kruskal-Wallis tests for continuous variables, and chi-square tests for categorical variables. P values were not adjusted for the multiplicity of secondary outcomes. ‡ Stunted was defined as a length-for-age z score lower than −2. § Weight-for-age, weight-for-length, and BMI-for-age z scores were obtained for 228 infants in the placebo group, 236 infants in the prenatal 4200 group, 237 infants in the prenatal 16,800 group, 229 infants in the prenatal 28,000 group, and 231 infants in the prenatal and postpartum 28,000 group. ¶ Head circumference-for-age z scores were obtained for 225 infants in the placebo group, 235 infants in the prenatal 4200 group, 234 infants in the prenatal 16,800 group, 229 infants in the prenatal 28,000 group, and 231 infants in the prenatal and postpartum 28,000 group.
‖ The sample sizes for mid-upper-arm circumference-for-age z score were the same as those for length-for-age z score. ** Wasted was defined as a weight-for-length z score lower than −2. † P values were calculated with the use of analysis of variance or Kruskal-Wallis tests for continuous variables, and chi-square or Fisher's exact tests for categorical variables. When the overall P value was significant, P values for pairwise tests were adjusted for multiple comparisons with the use of the Holm test; however, the values were not adjusted for the multiplicity of secondary outcomes. ‡ Two infants (one in the placebo group and one in the prenatal 16,800 group) were born at a location other than a hospital or clinic or at home; all other deliveries that did not occur at a medical facility took place at home.
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